IRIS
PLAZZI, Pier Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.061
AS - Asia 2.386
EU - Europa 2.097
SA - Sud America 319
AF - Africa 125
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 3
Totale 8.011
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.970
SG - Singapore 849
CN - Cina 754
FI - Finlandia 480
VN - Vietnam 347
SE - Svezia 329
IE - Irlanda 280
DE - Germania 267
BR - Brasile 247
UA - Ucraina 233
HK - Hong Kong 169
IT - Italia 157
GB - Regno Unito 86
NL - Olanda 74
ZA - Sudafrica 74
FR - Francia 69
TR - Turchia 68
CA - Canada 66
BD - Bangladesh 62
AR - Argentina 30
CI - Costa d'Avorio 28
IN - India 28
BE - Belgio 27
RU - Federazione Russa 21
PL - Polonia 16
MX - Messico 15
AT - Austria 14
IQ - Iraq 14
CZ - Repubblica Ceca 13
EC - Ecuador 13
JP - Giappone 13
PH - Filippine 11
TH - Thailandia 10
ES - Italia 9
ID - Indonesia 7
KR - Corea 7
VE - Venezuela 7
CO - Colombia 6
JO - Giordania 6
MA - Marocco 6
LT - Lituania 5
PK - Pakistan 5
SA - Arabia Saudita 5
AZ - Azerbaigian 4
BO - Bolivia 4
IR - Iran 4
PE - Perù 4
UZ - Uzbekistan 4
BY - Bielorussia 3
EG - Egitto 3
ET - Etiopia 3
LB - Libano 3
NP - Nepal 3
TN - Tunisia 3
UY - Uruguay 3
AO - Angola 2
AU - Australia 2
CL - Cile 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
LV - Lettonia 2
LY - Libia 2
NI - Nicaragua 2
OM - Oman 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
CR - Costa Rica 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
KE - Kenya 1
KZ - Kazakistan 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
QA - Qatar 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 7.991
Salva come PNG Salva come JPEG
Città #
Singapore 429
Ashburn 307
Chandler 307
Dublin 280
Jacksonville 275
San Jose 220
Santa Clara 196
Beijing 173
Hong Kong 162
Dallas 136
Ann Arbor 134
Dearborn 127
Ho Chi Minh City 108
Boardman 103
Council Bluffs 92
Nanjing 87
New York 82
Johannesburg 69
Munich 67
Los Angeles 63
Hanoi 61
Princeton 55
Izmir 54
San Mateo 50
Shanghai 49
Lauterbourg 45
Toronto 39
Wilmington 37
Helsinki 36
Hefei 34
Nanchang 30
Shenyang 29
Abidjan 28
Jinan 28
Brussels 27
Frankfurt am Main 24
Hebei 24
São Paulo 24
Bremen 23
Turku 23
Buffalo 22
Columbus 20
Des Moines 19
Haiphong 19
Kunming 18
Parma 18
Da Nang 15
Changsha 14
Moscow 14
Tianjin 14
Vienna 14
Woodbridge 14
Jiaxing 13
London 13
Grafing 12
The Dalles 11
Tokyo 11
Guangzhou 10
Milan 10
Montreal 10
Warsaw 10
Brooklyn 9
Phoenix 9
Rio de Janeiro 9
Ankara 8
Hangzhou 8
Norwalk 8
Orem 8
Brno 7
Chennai 7
Denver 7
Falkenstein 7
Auburn Hills 6
Augusta 6
Belo Horizonte 6
Curitiba 6
Dhaka 6
Mordano 6
Poplar 6
Redondo Beach 6
Seattle 6
Wuhan 6
Zhengzhou 6
Amman 5
Bexley 5
Biên Hòa 5
Caracas 5
Charlotte 5
Chengdu 5
Chicago 5
Cordoba 5
Falls Church 5
Genoa 5
Guarulhos 5
Guayaquil 5
Mexico City 5
Pune 5
Amsterdam 4
Atlanta 4
Baghdad 4
Totale 4.673
Salva come PNG Salva come JPEG
Nome #
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 223
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 213
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 209
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 208
Comparison of the effects of structurally different H2-antagonists on acid and pepsin activity stimulated by dimaprit in conscious cats 199
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 199
Azionifarmacologiche di composti alchilaminoalchilfenilbenzisotiazolici sul trattogastrointestinale 197
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 196
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 196
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 185
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 183
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 179
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 169
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 166
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 161
A Short and Efficient Synthesis of the Selective H4 Receptor Agonist 4-Methylhistamine 160
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 158
H3-antagonists: synthesis and activity of 2-amino-5-thiazolyl derivatives 157
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 156
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 151
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 151
Structural researcheson H^-agonists: the structures of the dipicrates of 2-(2-amino-4-imidazolyl)ethylamine, its 5-methyl derivative and N^f-dimeihyl-2-(2-am'mo-l,3-thiazol-5-yl)ethylamine 147
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 144
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 143
Hz-agonistiimidazolici: importanza della 2-amino sostituzione per 1'attivita farmacologica 142
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 139
Indole-based analogs of melatonin: in vitro antioxidant and cytoprotective activities 138
HPLC detection ofthioperamide from biological samples and its determination in rat blood and brainafter systemic administration 137
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 135
Tricyclic Alkylamides as Melatonin Receptor Ligands with Antagonist or Inverse Agonist Activity 133
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 131
Three-Dimensional Quantitative Structure-Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands: Requirements for Subtype Selectivity and Intrinsic Activity Modulation 130
Auxin-like activity of 1,2-benzisothiazole derivatives 124
Design, synthesis and SAR of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors 122
Synthesis, antioxidant activity and structure-activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity 122
H3-receptor antagonists: Synthesis and structure relationships of para- and meta-substituted 4(5)-phenyl-2-((2-(4(5)-imidazolyl)ethyl)thio)imidazoles 119
QSAR study on H3-receptor affinity of benzothiazole derivatives of thioperamide 119
Pharmacological activities of two new histamine analogs 117
Influence of urea-equivalent groups in position 5 of 2-amino, 2-(1-aminoethylidenamino) and 2-guanidino thiazole derivatives on H3-receptor antagonist activity in gastric fistula cat 115
Structure-Property Relationships on Histamine H3-Antagonists: Binding of Phenyl-substituted Alkylthioimidazole Derivatives to Rat Plasma Proteins 113
Pharmacological profile of original potent H3 receptor antagonists 113
Ligands for the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type 112
Sviluppo e caratterizzazione farmacologica di un nuovo potente e selettivo H3-bloccante istaminico non-tioureico 111
Imidazole H3-antagonists: Relationship between Structure and Ex-vivo binding to Rat Brain H3-Receptors 111
Antipyreticactivity of new compounds 4-(3-oxo-l,2-benzisothiazolin-2-yl)puenyialkanoicacids, their esters, amides and 1,1 dioxide derivatives 108
Synthesis and Structure-Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring 108
Studio di sostanze analoghe alDimaprit sulla secrezione gastrica "in vitro" 103
Rat protein binding and cerebral phospholipid affinity of the H3-receptor antagonist thioperamide 102
The 1,2-dichloroethane/water versus the n-octanol/water system: more about intra- or intermolecular H-bond interactions 102
Synthesis and Structure-Activity Relationships of a Series of Pyrrole Cannabinoid Receptor Agonists 102
Pharmacological characterization of H3 receptor antagonists with imidazole, thioimidazole and thioimidazoline polar groups in the side chain 101
Synthesis and stability in biological media of 1H-imidazole-1-carboxylates of ROS203, an antagonist of the histamine H3 receptor. 99
Are histamine receptors involved in the stimulant activities ofthiazolylethylamines supposed as cyclic models of dimaprit? 94
Synthesis, Pharmacological Characterization and QSAR Studies on 2-Substituted Indole Melatonin Receptor Ligands 94
Melatonin 91
Melatonin Receptor Ligands: Synthesis of New Melatonin Derivatives and Comprehensive Comparative Molecular Field Analysis (CoMFA) Study. 76
null 61
null 37
Totale 8.011
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.597
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022314 0 2 3 28 12 26 41 44 22 22 27 87
2022/20231.177 146 125 80 92 107 148 19 63 345 18 27 7
2023/2024365 22 33 6 12 28 118 33 21 10 18 21 43
2024/20251.246 41 70 79 71 80 140 31 72 153 128 123 258
2025/20262.744 221 259 287 284 388 204 269 98 391 206 92 45
2026/2027178 49 129 0 0 0 0 0 0 0 0 0 0
Totale 8.011